How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Rybrevant	AMIVANTAMAB	Johnson & Johnson		EGFR, MET	2021-01-01
Exkivity	MOBOCERTINIB	Takeda	Kinase Inhibitor	Receptor tyrosine-protein kinase erbB-4	2021-01-01
RYBREVANT	AMIVANTAMAB-VMJW	JANSSEN BIOTECH		Epidermal growth factor receptor, Hepatocyte growth factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

JANSSEN BIOTECH · 1 drug in Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Johnson & Johnson · 1 drug in Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations
Takeda · 1 drug in Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations:

Cite this brief

Drug Landscape (2026). Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations. Accessed 2026-06-10.

Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing